Patient characteristics according to bone marrow status
| . | Negative BM, n (%) . | Positive BM, n (%) . | All patients, n (%) . | |||
|---|---|---|---|---|---|---|
| Age (mean, SD), n = 42 | 44.82 ± 9.93 | 39.41 ± 12.07 | 43.38 ± 11.15 | |||
| Menopausal status, n = 42 | ||||||
| Premenopausal | 14 (60.9) | 13 (68.4) | 27 (64.3) | |||
| Postmenopausal | 9 (39.3) | 6 (31.6) | 15 (35.7) | |||
| Stage at diagnosis, n = 42 | ||||||
| II | 11 (47.8) | 2 (10.5) | 13 (30.9) | |||
| III | 10 (43.5) | 6 (31.6) | 16 (38.1) | |||
| IV | 2 (8.7) | 11 (57.9) | 13 (31) | |||
| BC histology, n = 42 | ||||||
| Ductal | 17 (73.9) | 17 (89.5) | 34 (81) | |||
| Lobular | 4 (17.4) | 2 (10.5) | 6 (14.2) | |||
| Other | 2 (8.7) | 2 (4.8) | ||||
| Tumor grade (SBR), n = 32 | ||||||
| Well differentiated (3-5) | 2 (11.1) | 1 (7.1) | 3 (9.4) | |||
| Moderately differentiated (6-7) | 8 (44.4) | 4 (28.6) | 12 (37.5) | |||
| Poorly differentiated (8-9) | 8 (44.4) | 9 (64.3) | 17 (53.1) | |||
| Estrogen receptors, n = 31 | ||||||
| Negative, 0 | 9 (47.4) | 5 (41.7) | 14 (45.2) | |||
| Positive, +, ++ | 9 (47.4) | 7 (58.3) | 16 (51.6) | |||
| Positive, +++ | 1 (5.3) | 1 (3.2) | ||||
| Progesterone receptor, n = 31 | ||||||
| Negative, 0 | 9 (47.4) | 6 (50) | 15 (48.4) | |||
| Positive, +, ++ | 9 (47.4) | 5 (41.7) | 14 (45.2) | |||
| Positive, +++ | 1 (5.3) | 1 (8.3) | 2 (6.5) | |||
| HER2NEU, n = 22 | ||||||
| Negative | 9 (69.2) | 5 (55.6) | 14 (63.6) | |||
| Positive | 4 (30.74) | 4 (44.4) | 8 (36.7) | |||
| . | Negative BM, n (%) . | Positive BM, n (%) . | All patients, n (%) . | |||
|---|---|---|---|---|---|---|
| Age (mean, SD), n = 42 | 44.82 ± 9.93 | 39.41 ± 12.07 | 43.38 ± 11.15 | |||
| Menopausal status, n = 42 | ||||||
| Premenopausal | 14 (60.9) | 13 (68.4) | 27 (64.3) | |||
| Postmenopausal | 9 (39.3) | 6 (31.6) | 15 (35.7) | |||
| Stage at diagnosis, n = 42 | ||||||
| II | 11 (47.8) | 2 (10.5) | 13 (30.9) | |||
| III | 10 (43.5) | 6 (31.6) | 16 (38.1) | |||
| IV | 2 (8.7) | 11 (57.9) | 13 (31) | |||
| BC histology, n = 42 | ||||||
| Ductal | 17 (73.9) | 17 (89.5) | 34 (81) | |||
| Lobular | 4 (17.4) | 2 (10.5) | 6 (14.2) | |||
| Other | 2 (8.7) | 2 (4.8) | ||||
| Tumor grade (SBR), n = 32 | ||||||
| Well differentiated (3-5) | 2 (11.1) | 1 (7.1) | 3 (9.4) | |||
| Moderately differentiated (6-7) | 8 (44.4) | 4 (28.6) | 12 (37.5) | |||
| Poorly differentiated (8-9) | 8 (44.4) | 9 (64.3) | 17 (53.1) | |||
| Estrogen receptors, n = 31 | ||||||
| Negative, 0 | 9 (47.4) | 5 (41.7) | 14 (45.2) | |||
| Positive, +, ++ | 9 (47.4) | 7 (58.3) | 16 (51.6) | |||
| Positive, +++ | 1 (5.3) | 1 (3.2) | ||||
| Progesterone receptor, n = 31 | ||||||
| Negative, 0 | 9 (47.4) | 6 (50) | 15 (48.4) | |||
| Positive, +, ++ | 9 (47.4) | 5 (41.7) | 14 (45.2) | |||
| Positive, +++ | 1 (5.3) | 1 (8.3) | 2 (6.5) | |||
| HER2NEU, n = 22 | ||||||
| Negative | 9 (69.2) | 5 (55.6) | 14 (63.6) | |||
| Positive | 4 (30.74) | 4 (44.4) | 8 (36.7) | |||
Abbreviations: BM, bone marrow; BC, breast cancer; SBR, Scarf Bloom Richardson.